AAV Capsid Engineering
CARE™ explores novel AAV vectors with improved on-target specificity offering clinical safety.
Candidate | Indication | Development status | ||||
---|---|---|---|---|---|---|
|
|
|
|
|||
Rare Genetic Disease | GXC-301 | Lafora disease |
In Vivo
ODD & RPDD granted by US FDA
|
|||
GXC-302 | Undisclosed |
In Vitro
|
||||
GXC-303 | ALS |
In Vivo
|
||||
GXC-304 | Fronto Temporal Dementia |
In Vivo
|
좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.
GENIXCURE, Selected for the project 'Development of AI-Based AAV Gene Delivery Technology and Gene Therapy'
Participating in the 2025 American Society of Gene & Cell Therapy (ASGCT),Announcing Research Results on "Engineering Next-Generation AAV Vectors for Enhanced ALS Therapy"
TOP